GHRH Analog Drug Development
The GHRH analog tesamorelin (trade name Egrifta) is a drug for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, approved by the U.S. Food and Drug Administration in November 2010. Chemically it is (3E)-hex-3-enoyl-GHRH. It may also reduce cognitive decline in older humans.
See also earlier work on Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys. CJC-1295, CJC-1293 and Sermorelin.
Read more about this topic: Growth-hormone-releasing Hormone
Famous quotes containing the words drug and/or development:
“Whoever grows angry amid troubles applies a drug worse than the disease and is a physician unskilled about misfortunes.”
—Sophocles (497–406/5 B.C.)
“The young women, what can they not learn, what can they not achieve, with Columbia University annex thrown open to them? In this great outlook for women’s broader intellectual development I see the great sunburst of the future.”
—M. E. W. Sherwood (1826–1903)